To include your compound in the COVID-19 Resource Center, submit it here.

The eagle flies

Raptor off on Phase III for Orphan drug as retail investors take profits

The eagle flies

Investors took profits last Monday after Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported that its RP103 met the non-inferiority primary endpoint in a Phase III trial to treat nephropathic cystinosis, an ultra-Orphan indication. The stock

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE